脑苷肌肽联合重组人组织型纤溶酶原激活物静脉溶栓对急性缺血性脑卒中患者血清超敏C反应蛋白、胰岛素样生长因子-1水平的影响  

Influence of cerebroside carnosine combined with intravenous thrombolysis with recombinant human tissue plasminogen activator on serum high-sensitivity C reactive protein and insulin-like growth factor-1levels in patients with acute ischemic stroke

作　　者：段淑娟 王雁飞 DUAN Shujuan;WANG Yanfei(Department of Neurology,Xi′an Hospital of Aviation Industry of China,Xi′an,Shaanxi,710077;Department of Neurology,Third Hospital of Xi′an,Xi′an,Shaanxi,710021)

机构地区：[1]中航工业西安医院神经内科,陕西西安710077 [2]陕西省西安市第三医院神经内科,陕西西安710021

出　　处：《实用临床医药杂志》2019年第20期11-14,共4页Journal of Clinical Medicine in Practice

摘　　要：目的 探讨脑苷肌肽联合重组人组织型纤溶酶原激活物(rt-PA)静脉溶栓对急性缺血性脑卒中患者血清超敏C反应蛋白(hs-CRP)、胰岛素样生长因子-1(IGF-1)水平的影响.方法 选取120例急性缺血性脑卒中患者,随机分为2组各60例.对照组采取rt-PA静脉溶栓治疗,研究组在对照组基础上加用脑苷肌肽注射液.比较2组治疗前及疗程结束后的日常生活能力(ADL)及美国国立卫生研究院卒中量表(NIHSS)评分、临床疗效、血清hs-CRP、IGF-1水平以及不良反应发生率.结果 研究组总有效率91.67%,显著高于对照组71.67% (P <0.05).2组疗程结束后NIHSS较治疗前显著降低,ADL较治疗前显著增高,且研究组显著优于对照组(P<0.05).疗程结束后,2组IGF-1水平显著高于治疗前,hs-CRP显著低于治疗前,且研究组显著优于对照组(P<0.05).研究组不良反应发生率15.00%,与对照组11.67%比较无显著差异(P>0.05).结论 应用rt-PA静脉溶栓联合脑苷肌肽注射液治疗急性缺血性脑卒中安全有效,可调节血清hs-CRP、IGF-1水平,改善神经功能及提高日常生活能力,且不会增加不良反应发生率.Objective To investigate the influence of cerebroside carnosine combined with intravenous thrombolysis with recombinant human tissue plasminogen activator(rt-PA)on serum high-sensitivity C reactive protein(hs-CRP)and insulin-like growth factor-1(IGF-1)levels in patients with acute ischemic stroke.Methods A total of 120 patients with acute ischemic stroke were selected and randomly divided into two groups,with 60 cases in each group.The control group was treated with rt-PA intravenous thrombolysis,while the study group was treated with cerebroside carnosine injection on the basis of the control group.The scores of Activities of Daily Living(ADL)and National Institutes of Health Stroke Scale(NIHSS),clinical efficacy,serum hs-CRP and IGF-1 levels,and the incidence rate of adverse reactions were compared between the two groups before and after treatment.Results The total effective rate was 91.67%in the study group,which was significantly higher than 71.67%in the control group(P<0.05).After treatment,the NIHSS score was significantly lower and ADL was significantly higher in both groups,and the scores in study group were significantly better than the control group(P<0.05).After treatment,the levels of IGF-1 and hs-CRP in both groups were significantly higher than those before treatment,and the level of hs-CRP in the study group was significantly higher than that in the control group(P<0.05).The incidence rate of adverse reactions in the study group was 15.00%,which showed no significant difference when compared to 11.67%in the control group(P>0.05).Conclusion Application of rt-PA intravenous thrombolysis combined with cerebroside carnosine injection is safe and effective in the treatment of acute ischemic stroke,which can regulate the levels of serum hs-CRP and IGF-1,improve nerve function and daily living ability,and does not increase the incidence rate of adverse reactions.

关 键 词：脑苷肌肽 重组人组织型纤溶酶原激活物 静脉溶栓 急性缺血性脑卒中 超敏C反应蛋白 胰岛素样生长因子-1 

分 类 号：R743.3[医药卫生—神经病学与精神病学]